ArticleBMC public health2025
Burden of hematologic malignancies in China from 1990 to 2021: analysis from the Global Burden of Disease Study 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure".Frontiers in oncology · 2026Review
- Effectiveness of a culturally adapted psychoeducational intervention for family caregivers of children with hematologic malignancy: a randomized controlled trial.Frontiers in psychiatry · 2026Article
- Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China.Frontiers in oncology · 2026Article
- Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWe aimed to provide epidemiological estimates and trend analysis based on average annual percentage change (AAPC) for age standardized rate (ASR) of hematologic malignancies in China from the Global Burden of Disease (GBD) Study 2021 to facilitate prevention strategies.
methodsWe estimated incidence, death, prevalence, and disability-adjusted life years (DALYs) for hematologic malignancies including leukemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL), which were defined by the International Classification of Diseases, Tenth Revision (ICD-10) in the period of 1990 to 2021 in China. Also, the relationship between sociodemographic index (SDI) and burden of hematologic malignancies was investigated by Pearson's Test. Besides, we analyzed risk factors attributed to death and disability-adjusted life-years (DALY) of hematologic malignancies.
resultsIn 2021, there were 1,215,635 individuals suffering from hematologic malignancies across China. According to AAPC for ASRs, large increasing trends were found in incidence and prevalence due to multiple myeloma (Incidence: 4.73, 95% CI 3.97 to 5.51; Prevalence: 6.43, 95% CI 5.86 to 7.00) and non-Hodgkin lymphoma (Incidence: 1.68, 95% CI 1.35 to 2.02; Prevalence: 4.92, 95% CI 4.39 to 5.45), while significant decreasing trends in death and DALYs due to leukemia (Death: -2.03, 95% CI -2.17 to -1.89; DALYs: -2.60, 95% CI -2.88 to -2.32) and HL(Death: -4.23, 95% CI -4.34 to -4.11; DALYs: -4.48, 95% CI -4.60 to -4.37). The AAPCs of death and DALYs for hematologic malignancies in China were nearly paralleled to the globe, whereas the AAPCs of incidence and prevalence were higher than the globe, except for HL. Positive correlations between age standardized incidence and prevalence rate of hematologic malignancies except for HL and SDI were observed, while inverse correlations between age standardized death and DALY rate of hematologic malignancies and SDI were found despite NHL. Tobacco and high body mass index were the leading risk factors related to hematologic malignancies.
conclusionsDespite some achievements on the burden of hematologic malignancies in China, there are still gaps with the world level. Formulation and implementation of health initiatives focusing on controlling tobacco use and high body mass index may alleviate the burden of hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.